The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - GlaxoSmithKline; Novartis; Qiagen
Honoraria - Alexion Pharmaceuticals; Amgen; Celgene; Merck Serono; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Celgene; Chugai Pharma; Janssen-Cilag; Merck Serono; Novartis; Roche; Sanofi
Lapatinib versus lapatinib plus capecitabine as second-line treatment in HER-2-overexpressing metastatic gastro-esophageal cancer (GC): A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
 
Sylvie Lorenzen
No Relationships to Disclose
 
Jorge Riera-Knorrenschild
Consulting or Advisory Role - Amgen; Baxter
 
Georg Martin Haag
No Relationships to Disclose
 
Michael Pohl
No Relationships to Disclose
 
Peter C. Thuss-Patience
No Relationships to Disclose
 
Florian Bassermann
No Relationships to Disclose
 
Ulrike Helbig
No Relationships to Disclose
 
Florian Weissinger
Consulting or Advisory Role - Lilly; Pfizer; Roche
 
Elisabeth Schnoy
No Relationships to Disclose
 
Klaus Becker
No Relationships to Disclose
 
Gertraud Stocker
No Relationships to Disclose
 
Josef Ruschoff
No Relationships to Disclose
 
Andreas Eisenmenger
No Relationships to Disclose
 
Irini Karapanagiotou-Schenkel
No Relationships to Disclose
 
Florian Lordick
Research Funding - Fresenius Biotech (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Merck Serono; Roche (I)